Incadronic acid
Alternative Names: Bisphonal; Incadronate; Incadronate disodium; YM 175; YM 211751Latest Information Update: 11 Apr 2005
Price :
$50 *
At a glance
- Originator Astellas Pharma
- Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
- Mechanism of Action Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Malignant hypercalcaemia
- No development reported Cancer metastases
- Discontinued Multiple myeloma; Periodontal disorders; Postmenopausal osteoporosis
Most Recent Events
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 30 Jul 2004 Discontinued - Phase-II for Periodontal disorders in Japan (Injection)
- 23 Oct 2003 This compound is still in active development for periodontal disease